The scope of the present study was: to describe the incidence of thromboembolic events (TE) in patients (pts) with resectable oesophagogastric (OG) adenocarcinoma receiving preoperative chemotherapy (CT) with curative intent; to assess risk factors of developing TE; to determine their impact on patient outcome.
Data from 590 pts with OG adenocarcinoma, who received epirubicin, cisplatin and capecitabine (ECX) or 5-fluorouracil (ECF) preoperatively in 3 UK hospitals, between 2009 & 2016, were collected retrospectively.
Median age was 66 years (range 28-85), 81% were males, 21% had gastric primaries, 98% received ECX chemotherapy, and 87% completed all 3 cycles of preoperative CT. In total, 52 pts (9%) had a venous and 22 (4%) an arterial event. Of patients with venous TE, 39 had pulmonary embolism and 13 deep vein thrombosis. Of patients with arterial TE, 7 developed cardiac infarct, 8 limb ischemia, 4 cerebrovascular accident and 3 superior mesenteric artery thrombosis. Arterial TE was associated with much higher inoperability rate compared to cases with venous TE or without TE (77% vs. 31% vs. 20% respectively, p
Preoperative ECX/ECF chemotherapy for patients with resectable OG adenocarcinoma was associated with relatively high incidence of TE. However, only arterial TE affected patient outcome
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.